Journal Article

Molecular insights into the rescue mechanism of an HERG activator against severe LQT2 mutations

Tavazzani, Elisa, Camilloni, Carlo, Kumawat, Amit, Denegri, Marco, Oldani, Amanda, Kukavica, Deni, Lentini, Giovanni, Trancuccio, Alessandro, Priori, Silvia G.

2025

Overview

Background Mutations in the HERG potassium channel are a major cause of long QT syndrome type 2 (LQT2), which can lead to sudden cardiac death. The HERG channel plays a critical role in the repolarization of the myocardial action potential, and loss-of-function mutations prolong cardiac repolarization. Methods In this study, we investigated the efficacy and underlying molecular mechanism of ICA-105574, an HERG activator, in shortening the duration of cardiac repolarization in severe LQT2 variants. We characterized the efficacy of ICA-105574 in vivo, using an animal model to assess its ability to shorten the QT interval and in vitro, in cellular models mimicking severe HERG channel mutations (A561V, G628S, and L779P) to evaluate its impact in enhancing I Kr current. Additionally, molecular dynamics simulations were used to investigate the molecular mechanism of ICA-105574 action. Results In vivo, ICA-105574 significantly shortened the QT interval. LQT2 mutations drastically reduced I Kr amplitude and suppressed tail currents in cellular models. ICA-105574 restored I Kr in A561V and G628S. Finally, in silico data showed that ICA-105574 stabilizes a pattern of interactions similar to gain-of-function SQT1 mutations and can reverse the G628S modifications, through an allosteric network linking the binding site to the selectivity filter and the S5P turret helix, thereby restoring its K + ion permeability. Conclusions Our results support the development of HERG activators like ICA-105574 as promising pharmacological molecules against some severe LQT2 mutations and suggest that molecular dynamics simulations can be used to test the ability of molecules to modulate HERG function in silico, paving the way for the rational design of new HERG activators.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Action potential / Allosteric properties / Animal models / Animals / Binding sites / Biomedical and Life Sciences / Biomedicine / Cardiology / Effectiveness / Electrocardiography / ERG1 Potassium Channel - genetics / ERG1 Potassium Channel - metabolism / Genetic aspects / Heart / HERG / HERG protein / Humans / ICA-105574 / In vivo methods and tests / Long QT syndrome / Long QT Syndrome - drug therapy / Long QT Syndrome - genetics / LQT2 / Molecular dynamics / Molecular Dynamics Simulation / Molecular modelling / Mutation / Potassium / Potassium channels / Potassium channels (voltage-gated) / Regression analysis / Simulation